Tremfya (guselkumab) — Medica

Initial criteria

• EITHER (age > 6 to < 17 years AND weight > 40 kg) OR age ≥ 18 years
• EITHER tried ≥ 1 traditional systemic agent for psoriasis for at least 3 months unless intolerant (e.g., methotrexate, cyclosporine, acitretin, or PUVA) OR contraindication to methotrexate OR has previously tried a biologic other than requested drug
• prescribed by or in consultation with a dermatologist

Reauthorization criteria

• patient has been established on requested drug for at least 3 months
• beneficial clinical response defined as improvement from baseline in at least one of: estimated body surface area, erythema, induration/thickness, or scale of areas affected by psoriasis
• improvement in at least one symptom such as decreased pain, itching, or burning

Approval duration

initial 3 months, reauth 1 year